Impact of long-term poor and good glycemic control on metabolomics alterations in type 1 diabetic people

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 4, 2016, Pages 1023-1033

  Dutta, Tumpa ^c   Kudva, Yogish C ^a   Persson, Xuan Mai T ^c   Schenck, Louis A ^b   Charles Ford, G ^c   Singh, Ravinder J ^c   Carter, Rickey ^b   Sreekumaran Nair, K ^a,c  

^a Divisions of Endocrinology and Endocrine Research Unit   (United Kingdom)

^b Biomedical Statistics and Informatics   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYADIPIC ACID; ACETIC ACID; ACETOACETIC ACID; ADIPIC ACID; ALANINE; BILE ACID; BUTYRIC ACID; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HEPTANOIC ACID DERIVATIVE; HISTIDINE; HOMOARGININE; HYDROXYBUTYRIC ACID; ICOSANOID; KETOL ACID REDUCTOISOMERASE; LEUCINE; LYSINE; METHIONINE; N,N DIMETHYL HISTIDINE; NONANOIC ACID; PROLINE; PROPIONIC ACID; RETINOL; SERINE; TRANSFER RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA; VALINE; VITAMIN D; AMINO ACID; FATTY ACID; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AMINO ACID METABOLISM; ARTICLE; CITRIC ACID CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCOLYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLOME; PRIORITY JOURNAL; RNA SYNTHESIS; VITAMIN METABOLISM; ANALYSIS; BLOOD; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; LIPID METABOLISM; METABOLISM; METABOLOMICS; MIDDLE AGED; RISK FACTOR;

ADULT; AMINO ACIDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FATTY ACIDS, NONESTERIFIED; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPID METABOLISM; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MIDDLE AGED; RISK FACTORS; VITAMIN D;

EID: 84960887455     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2640     Document Type: Article

References (40)

1. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction ofhypoglycemia. N Engl J Med. 2013;69:224-232.
2. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311-320.
3. Siegelaar SE, Holleman F, Hoekstra JB, De Vries JH. Glucose variability; does it matter? Endocr Rev. 2010;31:171-182.
4. Lachin JM, Orchard TJ, Nathan DM. Group ftDER. Update on cardiovascular outcomes at 30 years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care. 2014;37:39-43.
5. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371: 313-325.
6. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371:1972-1982.
7. Suhre K. Metabolic profiling in diabetes. J Endocrinol. 2014;221: R75-R85.
8. Roberts LD, Koulman A, Griffin JL. Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabo-lome. Lancet Diabetes Endocrinol. 2014;2:65-75.
9. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2013;17:448-453.
10. Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, New-gard CB. 2009 Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes. 2011;58:2429-2443.
11. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributestoinsulin resistance. Cell Metab. 2009;9:311-326.
12. Lanza IR, Zhang S, Ward LE, Karakelides H, Raftery D, Nair KS. Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS One. 2010;5:e10538.
13. Dutta T, Chai HS, Ward LE, et al. Concordance of changes in metabolic pathways based on plasma metabolomics and skeletal muscle transcriptomics in type 1 diabetes. Diabetes. 2012;61:1004-1016.
14. Irving BA, Weymiller AJ, Syed H, Karakelides H, Soop M, Carter RE, Nair KS. Amino acid metabolites and insulin resistance in human. Diabetes. 2011;60(suppl 1):A464.
15. Trushina E, Dutta T, Persson XM, Mielke MM, Petersen RC. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS One. 2013;8:e63644.
16. Persson X-MT, Błachnio-Zabielska AU, Jensen MD. Rapid measurement of plasma free fatty acid concentration and isotopic enrichment using LC/MS. J Lipid Res. 2010;51:2761-2765.
17. Koek MM, Muilwijk B, vander Werf MJ, Hankemeier T. Microbial metabolomics with gas chromatography/mass spectrometry. Anal Chem. 2006;78:1272-1281.
18. Storey JD. A direct approach to false discovery rates. J R Stat Soc B. 2002;64:479-498.
19. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003;100:9440-9445.
20. Dungan KM. 1, 5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn. 2008;8:9-19.
21. Liebich HM, Forst C. Hydroxycarboxylic and oxocarboxylic acids in urine-products from branched-chain amino-acid degradation and from ketogenesis. J Chromatogr. 1984;309:225-242.
22. Weber G, Lui MS, Jayaram HN, et al. Regulation of purine and pyrimidine metabolism by insulin and by resistance to tiazofurin. Adv Enzyme Regul. 1985;23:81-99.
23. Weinstein AL, Lalezarzadeh FD, Soares MA, Saadeh PB, Ceradini DJ. Normalizing dysfunctional purine metabolism accelerates diabetic wound healing. Wound Repair Regen. 2015;23(1):14-21.
24. Nair KS, Ford GC, Ekberg K, Fernqvistforbes E, Wahren J. Protein dynamics in whole-body and in splanchnic and leg tissues in type 1 diabetic-patients. J Clin Invest. 1995;95:2926-2937.
25. Wang TJ, Ngo D, Psychogios N, et al. 2-Aminoadipic acid is a biomarker for diabetes risk. J Clin Invest. 2013;123:4309-4317.
26. Meek SE, Nair KS, Jensen MD. Insulin regulation of regional free fatty acid metabolism. Diabetes. 1999;48:10-14.
27. Jensen MD, Caruso M, Heiling V, Miles JM. Insulin regulation of lipolysis in nondiabetic and IDDM subjects. Diabetes. 1989;38: 1595-1601.
28. Luo P, Wang M-H. Eicosanoids, β-cell function, and diabetes. Prostaglandins Other Lipid Mediat. 2011;95:1-10.
29. Metz S, Van Rollins M, Strife R, Fujimoto W, Robertson RP. Lipoxygenase pathway in islet endocrine cells. Oxidative metabolism of arachidonic acid promotes insulin release. J Clin Invest. 1983; 71:1191-1205.
30. Robertson RP, Chen M. A role for prostaglandin E in defective insulin secretion and carbohydrate intolerance in diabetes mellitus. J Clin Invest. 1977;60:747-753.
31. Ehses JA, Donath MY. Targeting 12-lipoxygenase as a novel strategy to combat the effects of inflammation on beta cells in diabetes. Diabetologia. 2015;58:425-428.
32. Weaver JR, Holman TR, Imai Y, et al. Integration of pro-inflammatory cytokines, 12-lipoxygenase and NOX-1 in pancreatic islet β cell dysfunction. Mol Cell Endocrinol. 2012;358:88-95.
33. Li X, Zhao G, Ma B, et al. 20-Hydroxyeicosatetraenoic acid impairs endothelial insulin signaling by inducing phosphorylation of the insulin receptor substrate-1 at Ser616. PLoS One. 2014;9:e95841.
34. Oresic M, Simell S, Sysi-Aho M, et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med. 2008;205:2975-2984.
35. Khan SA, Ali A, Zahran SA, Damanhouri G, Azhar E, Qadri I. Unraveling the complex relationship triad between lipids, obesity, and inflammation. Mediators Inflamm. 2014;2014:502749.
36. Androulakis II, Kaltsas GA, Kollias GE, et al. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J Clin Endocrinol Metab. 2014;99:2754-2762.
37. Sivitz WI, Chertow BS, Baranetsky NC, Clark SA, Waite A, Deluca HF. The effects of vitamin-D deficiency and repletion on rat insulin-secretion. Calcified Tissue Int. 1983;35:703-703.
38. Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia. 2005;48:1247-1257.
39. Lombardi F, Franzese A, Iafusco D, et al. Bone involvement in clusters of autoimmune diseases: just a complication? Bone. 2010;46: 551-555.
40. Thrailkill KM, Jo CH, Cockrell GE, Moreau CS, Fowlkes JL. Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency? J Clin Endocrinol Metab. 2011;96: 142-149.